This study proved that IL-1β pathway inhibition can achieve cardiovascular secondary prevention independent of lipid-lowering, but requires careful risk-benefit assessment regarding infection risks, highlighting the need for optimized dosing and patient stratification in targeted anti-inflammatory therapy. This evidence concerns the gene IL1B and infection.